Mild Cognitive Impairment

BAN2401

Allan Levey, MD, PhD

This multinational study is using a placebo or the study drug, BAN240, to determine clinical efficacy and to explore the dose response of this drug.  BAN2401 is an 18-month study in which drug/placebo is infused biweekly (once every 2 weeks). Subjects will be from 2 clinical subgroups: MCI due to Alzheimer's disease (AD) or mild Alzheimer's disease dementia. Effectiveness of drug treatment will be assessed using cognitive tests, as well as biological markers (MRI, PET, CSF, blood).

For more information about this research study, please call Gail Schwartz at 404-728-6395 or email gschwar@emory.edu.

Link to study website »


Atomoxetine Clinical Trial:

Allan Levey, MD, PhD
Director Emory Alzheimer's Disease Research Center, Chair, Emory University Department of Neurology

The purpose of this study is to find out if atomoxetine causes a change in the biological markers (substances that may indicate the presence of a disease) in the cerebrospinal fluid (CSF) of participants diagnosed with Mild Cognitive Impairment (MCI).  In this research study, the spinal fluid of subjects with MCI who take atomoxetine will be compared to spinal fluid of those who take capsules containing inactive material, also known as placebo. At the six-month time point, subjects who were taking placebo during the first six months will be placed on active study medication, and those who received active study medication will be reassigned to placebo. This study will also evaluate if the drug is safe and well-tolerated. Additionally, information will be gathered to identify the dose of atomoxetine that is most beneficial, and how taking this medication affects thinking and behavior, as well as imaging and blood biomarkers.

For more information about this research study, please call Lavezza Zanders at 404-728-6392 or email lzander@emory.edu.

Link to study website »


Emory Alzheimer's Disease Research Center Honor Research Registry

James Lah, MD, PhD
Clinical Core Leader, Emory Alzheimer's Disease Research Center

Felicia Goldstein, PhD
Clinical Core Co-Leader, Emory Alzheimer's Disease Research Center

Link to study flyer »

The purpose of Honor is to have a group of volunteers who want to participate in future research studies on memory & thinking.    By joining Honor you will learn about new research studies that are seeking volunteers.  You will also receive our newsletter and invitations to educational events. 

All Honor volunteers must have a “study partner” accompany them to their research visit.  Your study partner will be asked questions about your memory and thinking.  They will also be asked about your day to day functioning.  A study partner is someone who has at least 10 hours of contact with you each week.

For more information about this research study, please call Letheshia Husbands at 404-728-6950 or email lhusban@emory.edu .


MK8931-019

The purpose of this trial is to assess the efficacy and safety of MK-8931 compared with placebo in the treatment of MCI due to AD, also known as prodromal AD. Participants will be randomized to receive placebo, or 12 mg or 40 mg MK-8931, once daily. The primary study hypothesis is that at least one MK-8931 dose is superior to placebo with respect to the change from baseline in the cognitive assessment scores at 104 weeks.

For more information about this research study, please call Phyllis Vaughn at 404-728-6567 or email pvaughn@emory.edu.